Last reviewed · How we verify
EFG PH20 SC
EFG PH20 SC is a monoclonal antibody targeting ephrin type-A receptor 4 (EphA4).
EFG PH20 SC is a monoclonal antibody targeting ephrin type-A receptor 4 (EphA4). Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | EFG PH20 SC |
|---|---|
| Sponsor | argenx |
| Drug class | Monoclonal antibody |
| Target | EphA4 |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
EphA4 is a receptor involved in neural crest cell migration and axon guidance. Inhibiting EphA4 has been shown to reduce inflammation and promote neural repair in various neurological conditions.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |